Content about Gut flora

December 27, 2012
Study: Stroke survivors lacking antioxidant carotenoids in their gut flora

Researchers at the University of Gothenburg along with the Chalmers University of Technology earlier this month demonstrated that an altered gut microbiota in humans is associated with symptomatic atherosclerosis and stroke.

GOTHENBURG, Sweden — Researchers at the University of Gothenburg along with the Chalmers University of Technology earlier this month demonstrated that an altered gut microbiota in humans is associated with symptomatic atherosclerosis and stroke. 

These findings were presented in a study published in Nature Communications on Dec. 4.

May 8, 2012
Study: Probiotics may be able to reduce antibiotic-associated diarrhea incidence

Consumption of probiotics is associated with a reduced risk of antibiotic-associated diarrhea, a common adverse effect of antibiotic use, according to a review and meta-analysis of previous studies published in the May 9 issue of JAMA, the Journal of the American Medical Association.

CHICAGO — Consumption of probiotics is associated with a reduced risk of antibiotic-associated diarrhea, a common adverse effect of antibiotic use, according to a review and meta-analysis of previous studies published in the May 9 issue of JAMA, the Journal of the American Medical Association.

February 9, 2012
FDA issues warning on PPI, H2 blocker antacids: May increase risk of CDAD

The Food and Drug Administration on Wednesday issued a public warning that the use of proton-pump inhibitors or H2 blockers may be associated with an increased risk of Clostridium difficile–associated diarrhea, or CDAD.

SILVER SPRING, Md. — The Food and Drug Administration on Wednesday issued a public warning that the use of proton-pump inhibitors or H2 blockers may be associated with an increased risk of Clostridium difficile–associated diarrhea, or CDAD.

Patients should immediately contact their healthcare professional and seek care if they take PPIs and develop diarrhea that does not improve, the agency stated.

July 19, 2011
New ProbioKid Vita+ aims to boost kids' immunity in winter

A new probiotic formula that features added vitamins has entered the market.

MONTREAL — A new probiotic formula that features added vitamins has entered the market.

ProbioKid Vita+, developed by Institut Rosell-Lallemand, combines a synbiotic formula of probiotic strains — Lactobacillus helveticus Rosell-52, Bifidobacterium bifidum Rosell-71 and Bifidobacterium infantis Rosell-33 — and a prebiotic (fructooligosaccharide, or FOS) with vitamins C and D. The product is designed to boost kids' immunity in the winter, the company said.

ProbioKid Vita+ recently was unveiled at the Vitafoods Europe trade show in Geneva.

May 31, 2011
Dificid gets nod as CDAD treatment

The Food and Drug Administration has approved a treatment for diarrhea caused by a bacterial infection.

SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for diarrhea caused by a bacterial infection.

The agency announced the approval of Optimer Pharmaceuticals’ Dificid (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea, also known as CDAD.

January 24, 2011
FDA accepts filing for CDI treatment

The Food and Drug Administration has accepted a regulatory filing from Optimer Pharmaceuticals for a drug to treat bacterial infections.

SAN DIEGO — The Food and Drug Administration has accepted a regulatory filing from Optimer Pharmaceuticals for a drug to treat bacterial infections.

Optimer announced Monday the FDA’s acceptance of its approval application for fidaxomicin for treating clostridium difficile infection, or CDI. CDI is a colon infection that is a particular problem in hospitals, long-term care centers and in the broader community. It is estimated to affect more than 700,000 people per year. The agency has granted the application priority review and expects to finish its review by May 30.

November 8, 2010
FDA grants fast-track designation for CDI vaccine

A vaccine for a bacterial infection that affects the gastrointestinal tract has been granted expedited...

SWIFTWATER, Pa. A vaccine for a bacterial infection that affects the gastrointestinal tract has been granted expedited approval by the Food and Drug Administration.

 

French drug maker Sanofi-Aventis announced Tuesday that it had received fast-track designation from the FDA for its investigational Clostridium difficile vaccine. The FDA grants the designation to ease the development of new drugs and vaccines for serious or life-threatening conditions or unmet medical needs.